T4R

CompletedPhase 4

Trial for People With Established Type 2 Diabetes During Ramadan

A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Liraglutide vs. a Sulphonylurea

Lead sponsor

University of Leicester

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Type 2 diabetes

Key I/E criterion

•HbA1c 7-11%

Primary endpoint

•Composite (Body weight, % change, HbA1c, change, Severe hypoglycemia)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02292290

Org study ID0207

Timeline

Milestones

Study first posted2014-11-17estimated

Last update posted2020-01-30actual

Study start2011-04 (month precision)

Primary completion2012-12actual (month precision)

Study completion2012-12actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Individuals ≥ 18 years old with established T2DM on metformin only

•or dual therapy of metformin plus a sulphonylurea or pioglitazone

•with a HbA1c between 7 - 11 % if on monotherapy and between 6.5 - 12% if on dual therapy

Exclusion criteria

•Are pregnant or breast feeding

•Suffer from terminal illness

•Have significant renal or liver impairment

•Are unable to provide informed consent

•Have severe and enduring mental health problems

•Are not primarily responsible for their own care

•Are receiving insulin therapy

•Type 1 diabetes

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint/low confidence

Composite

Time frame:12 weeks following post Ramadan cinical assessment

composite event, improvement

componentsBody weight, % change, HbA1c, change, Severe hypoglycemia

Secondary/protocol endpoint

HbA1c only

Time frame:same as primary, 12 weeks following post Ramadan cinical assessment

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.